Global Biosimilar Market Size By Type (Human Growth Hormones, Monoclonal Antibodies), By Application (Oncology, Chronic and Autoimmune Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Biosimilar Market was valued at USD 22.1 billion in 2023 and is projected to reach USD 85.6 billion by 2031, growing at a CAGR of 18.2% during the forecast period from 2023 to 2031. The market is experiencing rapid expansion driven by increasing patent expirations of biologic drugs, rising demand for cost-effective treatment alternatives, and strong support from healthcare systems for biosimilar adoption. As biologics become central to treating chronic diseases like cancer, diabetes, and autoimmune conditions, biosimilars offer a promising solution to enhance accessibility and reduce treatment costs globally.

Drivers:

Patent Expiry of Major Biologics:

A wave of patent expirations for blockbuster biologics is fueling biosimilar development. As originator biologics lose exclusivity, biosimilars enter the market at reduced prices, expanding access and spurring competition.

Rising Prevalence of Chronic Diseases:

The growing global burden of chronic diseases, including cancer, rheumatoid arthritis, and diabetes, is driving demand for affordable, long-term treatment options. Biosimilars are becoming integral in addressing these needs without compromising therapeutic efficacy.

Government and Payer Support:

Healthcare systems worldwide are actively encouraging biosimilar uptake through incentives, pricing reforms, and streamlined regulatory pathways, particularly in Europe and emerging markets.

Restraints:

Regulatory and Development Complexities:

Biosimilar development involves rigorous clinical evaluations, analytical characterization, and approval processes, which are cost-intensive and time-consuming, particularly for smaller biotech firms.

Physician and Patient Reluctance:

Despite clinical equivalence, initial hesitation among healthcare providers and patients regarding biosimilar substitution remains a challenge in certain regions, limiting market penetration.

Opportunity:

Expansion in Emerging Markets:

Developing economies are witnessing increased investment in biosimilar production and regulatory alignment, presenting significant growth opportunities due to rising healthcare access and affordability priorities.

Advancement in Manufacturing Technologies:

Technological innovations in bioprocessing and analytical tools are reducing development timelines and improving the scalability of biosimilars, enabling manufacturers to cater to larger patient pools.

Market by System Type Insights:

The Monoclonal Antibodies (mAbs) segment accounted for the largest share of the market in 2023. mAbs are critical in treating cancer and autoimmune disorders, and the increasing number of biosimilar approvals in this category is bolstering segment growth. The Insulin Biosimilars segment is also expanding swiftly, fueled by the global diabetes burden and cost-containment initiatives.

Market by End-use Insights:

Hospital Pharmacies emerged as the leading end-use segment in 2023, attributed to the high volume of biosimilar prescriptions in inpatient settings. Retail Pharmacies are expected to see the highest growth rate during the forecast period, driven by increased awareness and expanded reimbursement coverage for biosimilars in outpatient care.

Market by Regional Insights:

Europe led the global biosimilar market in 2023, owing to early regulatory adoption and favorable policies promoting biosimilar use. Asia-Pacific is anticipated to witness the fastest growth, driven by increasing healthcare expenditure, rapid regulatory reforms, and a growing biologics market in countries such as India, China, and South Korea.

Competitive Scenario:

Key players in the global biosimilar market include Sandoz (a Novartis division), Pfizer Inc., Celltrion Inc., Samsung Bioepis, Amgen Inc., Biocon Biologics, Fresenius Kabi, Mylan N.V., Dr. Reddy’s Laboratories, and STADA Arzneimittel AG. These companies are focusing on regulatory approvals, strategic partnerships, and global expansion.

In 2024, Biocon Biologics completed the acquisition of Viatris' biosimilars portfolio, enhancing its global distribution capabilities.

Pfizer launched a trastuzumab biosimilar in key Asian markets in 2023 to strengthen its oncology portfolio.

Samsung Bioepis entered a co-commercialization agreement with Organon in 2022, expanding biosimilar accessibility in North America and Europe.

Scope of Work – Global Biosimilar Market

Key Market Developments:

May 2024: Amgen secured FDA approval for its biosimilar to Soliris, entering the rare disease market.

February 2024: STADA and Alvotech received EMA approval for their biosimilar to Humira, with rollout across 15 European countries.

July 2023: Celltrion submitted its biosimilar application for ustekinumab (Stelara) to the US FDA, targeting launch in early 2025.

FAQs:

What is the current market size of the Global Biosimilar Market?

The Global Biosimilar Market was valued at USD 22.1 billion in 2023.

What is the major growth driver of the Global Biosimilar Market?

The expiration of patents for key biologics and growing demand for cost-effective treatments are major growth drivers.

Which is the largest region during the forecast period in the Global Biosimilar Market?

Europe is the largest region, benefiting from robust regulatory frameworks and biosimilar adoption.

Which segment accounted for the largest market share in the Global Biosimilar Market?

The Monoclonal Antibodies segment held the largest share in 2023.

Who are the key market players in the Global Biosimilar Market?

Key players include Sandoz, Pfizer, Celltrion, Samsung Bioepis, Biocon, and Amgen.